BYSI vs. VTVT, ASMB, AVRO, BLRX, SABS, BCLI, LIAN, ACST, LPCN, and TCRT
Should you be buying BeyondSpring stock or one of its competitors? The main competitors of BeyondSpring include vTv Therapeutics (VTVT), Assembly Biosciences (ASMB), AVROBIO (AVRO), BioLineRx (BLRX), SAB Biotherapeutics (SABS), Brainstorm Cell Therapeutics (BCLI), LianBio (LIAN), Acasti Pharma (ACST), Lipocine (LPCN), and Alaunos Therapeutics (TCRT). These companies are all part of the "medical" sector.
BeyondSpring (NASDAQ:BYSI) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations, community ranking and risk.
In the previous week, vTv Therapeutics' average media sentiment score of 1.05 beat BeyondSpring's score of 0.00 indicating that vTv Therapeutics is being referred to more favorably in the news media.
vTv Therapeutics received 166 more outperform votes than BeyondSpring when rated by MarketBeat users. However, 66.79% of users gave BeyondSpring an outperform vote while only 57.83% of users gave vTv Therapeutics an outperform vote.
40.3% of BeyondSpring shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 29.3% of BeyondSpring shares are owned by insiders. Comparatively, 1.7% of vTv Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
vTv Therapeutics has higher revenue and earnings than BeyondSpring.
BeyondSpring has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Comparatively, vTv Therapeutics has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500.
BeyondSpring presently has a consensus price target of $1.25, indicating a potential downside of 44.93%. Given BeyondSpring's higher probable upside, analysts clearly believe BeyondSpring is more favorable than vTv Therapeutics.
Summary
BeyondSpring beats vTv Therapeutics on 6 of the 11 factors compared between the two stocks.
Get BeyondSpring News Delivered to You Automatically
Sign up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BYSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BeyondSpring Competitors List
Related Companies and Tools
